Abp-788.mp4

The "guide" in the video likely explains the :

ARX788 is a site-specific ADC designed to target and HER2-low cancers. Unlike traditional therapies, it uses a unique non-natural amino acid technology to link a potent toxin directly to an antibody, ensuring the "payload" is delivered specifically to cancer cells while sparing healthy tissue. 1. Clinical Applications & Efficacy

If the video discusses trial results, it likely highlights these key areas: ABP-788.mp4

: A potent tubulin inhibitor that kills the cancer cell once the antibody binds to the HER2 receptor and is internalized.

: In the ACE-Breast-02 trial , ARX788 significantly improved progression-free survival (PFS) to 11.3 months compared to 8.2 months for standard treatments. The "guide" in the video likely explains the

: Ongoing research is exploring its use in patients with lower levels of HER2 expression, who previously had limited targeted therapy options. 2. Mechanism of Action

Below is a draft guide based on the clinical profile of the ARX788 therapy, which the video likely covers. Clinical Applications & Efficacy If the video discusses

: Recent data from the ACE-Breast-06 study showed that ARX788 can cross the blood-brain barrier, providing a 25% objective response rate for patients with active brain metastases.